SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
2.120
0.00 (0.00%)
At close: Sep 12, 2025, 4:00 PM EDT
2.100
-0.020 (-0.94%)
After-hours: Sep 12, 2025, 7:57 PM EDT
SAB Biotherapeutics Revenue
SAB Biotherapeutics had revenue of $114.70K in the twelve months ending June 30, 2025, down -95.87% year-over-year. In the year 2024, SAB Biotherapeutics had annual revenue of $1.32M, down -40.94%.
Revenue (ttm)
$114.70K
Revenue Growth
-95.87%
P/S Ratio
171.60
Revenue / Employee
$1,821
Employees
63
Market Cap
22.07M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.32M | -916.58K | -40.94% |
| Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
| Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
| Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
| Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SABS News
- 10 days ago - SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes - GlobeNewsWire
- 5 weeks ago - SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates - GlobeNewsWire
- 7 weeks ago - SAB BIO Announces Oversubscribed $175 Million Private Placement - GlobeNewsWire
- 4 months ago - SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates - GlobeNewsWire
- 5 months ago - SAB BIO Reports Full Year 2024 Operating and Financial Results - GlobeNewsWire
- 8 months ago - SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 8 months ago - Why Is SAB BIO Stock Trading Lower On Tuesday? - Benzinga
- 8 months ago - SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 - GlobeNewsWire